Abstract
Aceclofenac is a non-steroidal anti-inflammatory, analgesic and antipyretic agent. It has short biological half-life (4 hours). The present study aims to formulate sustained release Matrix tablet of Aceclofenac for improved patient compliance, better therapeutic efficacy, less side effects and reduced dosage regimen with less toxicity. Total six formulations (F1-F6) were prepared with varying ratios of Eudragit RS100 and Carbopol 934P as matrix forming agents and evaluated for various pre-compression and post compression parameters. Formulation (F3) containing 1:1 ratio of Eudragit RS100 and Carbopol 934P showed promising results in dissolution studies when compared to the rest of the formulations.
 Keywords: Aceclofenac, Matrix Tablets, Eudragit, Carbopol, Sustained Release.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
